Peptides for mood: what TikTok gets wrong about the science

What did @teekaxoxo actually say?

She described taking selank as a nasal spray before a nursing shift, feeling effects within 50-60 minutes, and staying in a "flow state" while charting, which is notoriously hard for her because of ADHD. She said her anxiety dropped, her mood lifted, and the effects lasted about six hours before she redosed at midnight. By 7:38 AM she still felt "wonderful." She ended by recommending semax as a follow-up peptide.

To her credit, she was specific. She gave a rough onset time, noted a wearing-off window, and mentioned a second dose. That kind of granularity is more useful than the average peptide TikTok, which usually stops at "it changed my life." She did not claim it cures ADHD or anxiety disorders, which matters legally and medically.

Does the science back this up?

Partially, and with real caveats. Selank is a synthetic heptapeptide derived from tuftsin, developed in Russia by the Institute of Molecular Genetics. It has been studied primarily in Russian clinical literature, which is a significant limitation for Western evidence standards.

The anxiolytic effects she described are the most supported claim. Seredenin and Voronina (2009, Eksperimental'naya i Klinicheskaya Farmakologiya) summarized animal and early human data showing selank modulates GABAergic and serotonergic activity, which aligns with reduced anxiety reports. A small Russian RCT by Uchakina et al. (2008) found selank improved anxiety scores in generalized anxiety disorder patients over 14 days.

The focus and ADHD angle is shakier. Selank has been shown in rodent models to increase BDNF expression and influence dopaminergic signaling (Poltavtseva et al., 2013, Bulletin of Experimental Biology and Medicine), but there are no peer-reviewed human trials specifically on ADHD populations. Her subjective "locked in" experience is plausible mechanistically, but calling it evidence is a stretch.

A six-hour duration window is consistent with reported half-life estimates for intranasal peptide delivery, though pharmacokinetic data on selank in humans is thin.

What did they get wrong (or right)?

She got the subjective experience report right in the sense that it was honest and time-stamped. What she got wrong, or at least incomplete, is the implied causal certainty. One shift does not establish that selank caused her focus improvement. Expectation effects in open-label self-experimentation are real and well-documented. A nurse charting at night with a new intervention she is excited about has every reason to feel more alert, regardless of the compound.

She also recommended stacking selank with semax without any qualification. Semax is another Russian nootropic peptide that influences ACTH-derived pathways and BDNF. Individually, both have limited but suggestive human data. Together, there are essentially no human combination studies. Recommending "both y'all together" to a TikTok audience with no clinical context is irresponsible, even if her personal enthusiasm is understandable.

She did not claim either peptide treats a disease, which keeps her out of the most dangerous category of peptide content. That is worth acknowledging.

What should you actually know?

Selank is not FDA-approved for any indication. It is available through compounding pharmacies in the United States under specific prescriber oversight, and it is not equivalent to any approved branded medication. Its research base is real but narrow, mostly Russian, and largely predates the kind of randomized controlled trial infrastructure that Western regulators require.

If you have ADHD and are curious about selank, the honest answer is that the mechanistic rationale is not implausible, the safety profile in short-term use appears relatively benign based on available data, but the evidence base does not yet support confident clinical recommendations. This is a legal and regulated compound when obtained through a licensed telehealth provider, not a supplement you self-prescribe based on a TikTok shift report.

The intranasal delivery route she used is pharmacologically relevant. Nasal administration can bypass the blood-brain barrier more efficiently than oral routes for certain peptides (Dhuria et al., 2010, Journal of Pharmaceutical Sciences), which is part of why onset at 50-60 minutes is plausible. But absorption variability between individuals is significant.

• Selank has documented anxiolytic effects in small human trials, but they are limited in scale and geographic scope.
• No peer-reviewed human data exists on selank for ADHD specifically.
• Stacking selank and semax has no published human safety or efficacy data.
• Subjective reports from single open-label use cannot separate drug effect from expectation.